Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2008

View Archived Issues

New target in hypertension: G12-G13-LARG-mediated signaling

Studies with AM-251 support CB1 receptor antagonism in smoking cessation

Fenofibrate shows antitumor activity via angiogenesis inhibition

Recent patents cover novel anticancer agents

Recent Merck & Co. patent imparts novel agents for ocular disorders

Recent patents disclose novel therapeutic agents for obesity

Morphotek enters collaborative research agreement with LICR for novel disease targets

Genentech presents full year and fourth quarter 2007 results

Apthera files a phase III SPA with the FDA for NeuVax in early breast cancer

AstraZeneca treats first patient in expanded phase II CytoFab program

FDA approves Taro's NDA for prednisolone acetate oral suspension

KV Pharmaceutical acquires rights to Gestiva

Novexel and Forest collaborate on NXL-104 combination therapy

Rubicon Genomics collaborates with OncoMethylome Sciences for cancer biomarkers

Vical receives payment from AnGes for phase III trial of Allovectin-7

FDA clears NovaBay's IND application to begin clinical trials of AgaNase

FDA places clinical hold on CytRx's phase IIb clinical trial of arimoclomol for ALS

NanoViricides locates facilities in which to initiate animal studies for HPAI treatments

Bristol-Myers exercises option to develop and commercialize Exelixis' XL-139

iCo and UBC reprofile amphotericin B into safer and more stable oral formulation

Indevus reports positive results from phase III trial of Nebido for male hypogonadism

Teva acquires CoGenesys

MolMed obtains approval to start a phase III HSV-TK gene therapy trial

Johnson & Johnson submits NDA in U.S. for immediate release tapentadol

FDA accepts NovaDel's NDA for ZolpiMist oral spray in the treatment of insomnia

Chelsea initiates phase II CH-1504 program in rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...